<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="39867">Valproic acid</z:chebi> has been previously associated with hematologic toxicity, including a reversible <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-like syndrome without chromosomal abnormalities </plain></SENT>
<SENT sid="1" pm="."><plain>We now report three cases of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> with features of secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> associated with <z:chebi fb="0" ids="39867">valproic acid</z:chebi> therapy: two cases of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, one with <z:mp ids='MP_0004027'>trisomy</z:mp> 8 and one with <z:mp ids='MP_0004026'>monosomy</z:mp> 7, and one case of secondary <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> with del (7) (q22q34), del (9) (q21.11q22), del (11) (q12q23) </plain></SENT>
<SENT sid="2" pm="."><plain>One patient had a previous <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> while on <z:chebi fb="0" ids="39867">valproic acid</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="39867">Valproic acid</z:chebi> has been previously shown to be a <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor </plain></SENT>
<SENT sid="4" pm="."><plain>Inhibition of <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase causes a relaxation of chromatin structure and thus increases susceptibility to DNA damage and sensitizes cells to radiation </plain></SENT>
<SENT sid="5" pm="."><plain>We propose that <z:chebi fb="0" ids="39867">valproic acid</z:chebi> therapy may lead to secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> by increasing DNA damage through <z:hpo ids='HP_0011010'>chronic</z:hpo> inhibition of <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase </plain></SENT>
</text></document>